Main Menu

Publications

Publications Highlights View all by category

Types of Publications


Journal Articles

Dearnaley, D., Griffin, C.L., Lewis, R., Mayles, P., Mayles, H., Naismith, O.F., Harris, V., Scrase, C.D., Staffurth, J., Syndikus, I., et al. (2019). Toxicity and Patient-Reported Outcomes of a Phase 2 Randomized Trial of Prostate and Pelvic Lymph Node Versus Prostate only Radiotherapy in Advanced Localised Prostate Cancer (PIVOTAL). International journal of radiation oncology*biology*physics, Vol.103 (3), pp. 605-617.

Walker, A.K., Karaszi, K., Valentine, H., Strauss, V.Y., Choudhury, A., McGill, S., Wen, K., Brown, M.D., Ramani, V., Bhattarai, S., et al. (2019). MRE11 as a Predictive Biomarker of Outcome After Radiation Therapy in Bladder Cancer. International journal of radiation oncology*biology*physics, Vol.104 (4), pp. 809-818.

Wilkins, A., Stuttle, C., Hassan, S., Blanchard, C., Cruickshank, C., Griffin, C., Probert, J., Corbishley, C.M., Parker, C., Dearnaley, D., et al. (2018). Methodology for tissue sample collection within a translational sub-study of the CHHiP trial (CRUK/06/016), a large randomised phase III trial in localised prostate cancer. Clinical and translational radiation oncology, Vol.10, pp. 1-6.

Wilson, J.M., Dearnaley, D.P., Syndikus, I., Khoo, V., Birtle, A., Bloomfield, D., Choudhury, A., Graham, J., Ferguson, C., Malik, Z., et al. (2018). The Efficacy and Safety of Conventional and Hypofractionated High-Dose Radiation Therapy for Prostate Cancer in an Elderly Population: A Subgroup Analysis of the CHHiP Trial. International journal of radiation oncology*biology*physics, Vol.100 (5), pp. 1179-1189.

Hague, C., Foran, B., Hall, E., Guild, S., Joseph, O., Moule, R., Nutting, C., Parsons, S., Prestwich, R., Slevin, N., et al. (2018). Patient Involvement in the Design of a Phase III Trial Comparing Intensity-modulated Proton Therapy and Intensity-modulated Radiotherapy for Oropharyngeal Cancer. Clinical oncology, Vol.30 (5), pp. 274-276.

Wilkins, A.C., Gusterson, B., Szijgyarto, Z., Haviland, J., Griffin, C., Stuttle, C., Daley, F., Corbishley, C.M., Dearnaley, D.P., Hall, E., et al. (2018). Ki67 Is an Independent Predictor of Recurrence in the Largest Randomized Trial of 3 Radiation Fractionation Schedules in Localized Prostate Cancer. International journal of radiation oncology*biology*physics, Vol.101 (2), pp. 309-315.

Nutting, C.M., Morden, J.P., Beasley, M., Bhide, S., Cook, A., De Winton, E., Emson, M., Evans, M., Fresco, L., Gollins, S., et al. (2018). Results of a multicentre randomised controlled trial of cochlear-sparing intensity-modulated radiotherapy versus conventional radiotherapy in patients with parotid cancer (COSTAR; CRUK/08/004). European journal of cancer, Vol.103, pp. 249-258.

Choudhury, A., West, C.M., Porta, N., Hall, E., Denley, H., Hendron, C., Lewis, R., Hussain, S.A., Huddart, R. & James, N., et al. (2017). The predictive and prognostic value of tumour necrosis in muscle invasive bladder cancer patients receiving radiotherapy with or without chemotherapy in the BC2001 trial (CRUK/01/004). British journal of cancer, Vol.116 (5), pp. 649-657.

Dearnaley, D., Syndikus, I., Mossop, H., Khoo, V., Birtle, A., Bloomfield, D., Graham, J., Kirkbride, P., Logue, J., Malik, Z., et al. (2016). Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: 5-year outcomes of the randomised, non-inferiority, phase 3 CHHiP trial. The lancet oncology, Vol.17 (8), pp. 1047-1060.

Harris, V.A., Staffurth, J., Naismith, O., Esmail, A., Gulliford, S., Khoo, V., Lewis, R., Littler, J., McNair, H., Sadoyze, A., et al. (2015). Consensus Guidelines and Contouring Atlas for Pelvic Node Delineation in Prostate and Pelvic Node Intensity Modulated Radiation Therapy. International journal of radiation oncology*biology*physics, Vol.92 (4), pp. 874-883.

Wilkins, A., Mossop, H., Syndikus, I., Khoo, V., Bloomfield, D., Parker, C., Logue, J., Scrase, C., Patterson, H., Birtle, A., et al. (2015). Hypofractionated radiotherapy versus conventionally fractionated radiotherapy for patients with intermediate-risk localised prostate cancer: 2-year patient-reported outcomes of the randomised, non-inferiority, phase 3 CHHiP trial. The lancet oncology, Vol.16 (16), pp. 1605-1616.

Mateo, J., Carreira, S., Sandhu, S., Miranda, S., Mossop, H., Perez-Lopez, R., Rodrigues, D.N., Robinson, D., Omlin, A., Tunariu, N., et al. (2015). DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer. The new england journal of medicine, Vol.373 (18), pp. 1697-1708.

James, N.D., Hussain, S.A., Hall, E., Jenkins, P., Tremlett, J., Rawlings, C., Crundwell, M., Sizer, B., Sreenivasan, T., Hendron, C., et al. (2012). Radiotherapy with or without chemotherapy in muscle-invasive bladder cancer. N engl j med, Vol.366 (16), pp. 1477-1488.  show abstract

Sharma, R.A., Plummer, R., Stock, J.K., Greenhalgh, T.A., Ataman, O., Kelly, S., Clay, R., Adams, R.A., Baird, R.D., Billingham, L., et al. Clinical development of new drug-radiotherapy combinations. Nat rev clin oncol, Vol.13 (10), pp. 627-642.  show abstract

Hall, E. Systematic review of methodology used in clinical studies evaluating the benefits of proton beam therapy Clinical and Translational Radiation Oncology. Clinical and translational radiation oncology, .

Hall, E., Brand, D., Tree, A., Ostler, P., van der Voet, H., Loblaw, A., Chu, W., Ford, D., Tolan, S., Jain, S., et al. Intensity Modulated Fractionated Radiotherapy Versus Stereotactic Body Radiotherapy for Prostate Cancer (PACE-B): Acute Toxicity Results From a Randomised Open-label Phase III Non-inferiority Trial. The lancet oncology, .